Sofomax Duo Tablet combines Ledipasvir 90 mg and Sofosbuvir 400 mg, providing a potent once-daily oral therapy for the treatment of chronic hepatitis C virus (HCV) infection. This combination is a direct-acting antiviral (DAA) regimen that targets multiple stages of the HCV lifecycle, offering high cure rates across multiple genotypes.

Ledipasvir inhibits the HCV NS5A protein, preventing viral replication and assembly, while Sofosbuvir, a nucleotide analog, inhibits NS5B RNA polymerase, stopping viral RNA synthesis. Together, they provide a synergistic effect for rapid viral clearance and improved liver function.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Ledipasvir 90 mg
• Sofosbuvir 400 mg

Mechanism of Action

• Ledipasvir: Inhibits the NS5A protein, which is essential for HCV replication, assembly, and secretion, reducing the production of new virus particles.
• Sofosbuvir: A nucleotide analog NS5B polymerase inhibitor that incorporates into viral RNA, causing chain termination and halting viral replication.
• The combination ensures comprehensive inhibition of HCV, promoting rapid viral clearance and sustained virologic response (SVR).

Indications

Sofomax Duo Tablet is indicated for:

• Chronic hepatitis C virus (HCV) infection, including genotypes 1, 4, 5, and 6
• Treatment for treatment-naïve or previously treated patients
• Patients with compensated liver disease (Child-Pugh A)
• Used as part of all-oral therapy, often without the need for interferon

Dosage & Administration

• Standard dosage: 1 tablet once daily, with or without food
• Typical treatment duration: 12 weeks, depending on genotype and prior treatment history
• Adherence to daily dosing is critical for achieving SVR and viral clearance
• Patients with cirrhosis or prior treatment failure may require extended therapy or additional medications as per physician guidance

Benefits

• High cure rates across multiple HCV genotypes
• Reduces liver inflammation and fibrosis
• Convenient once-daily oral dosing
• Interferon-free regimen, reducing systemic side effects
• Supports overall liver health and prevents long-term complications such as cirrhosis or liver cancer

Possible Side Effects

Common side effects:

• Fatigue
• Headache
• Nausea
• Insomnia

Less common but serious side effects:

• Anemia (especially if co-administered with ribavirin)
• Liver enzyme elevations
• Severe allergic reactions (rare)

Precautions & Warnings

• Not recommended in severe hepatic impairment (Child-Pugh C) without specialist supervision
• Consult a physician for pregnancy and breastfeeding, as safety has not been fully established
• Inform the doctor about all medications to avoid potential interactions
• Monitor liver function tests and viral load during therapy
• Avoid alcohol and hepatotoxic drugs during treatment

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Storage

• Store at 20–25°C in a dry, cool place
• Protect from light, moisture, and heat
• Keep out of reach of children

Conclusion

Sofomax Duo Tablet 90 mg + 400 mg (Ledipasvir + Sofosbuvir) is a highly effective, all-oral antiviral therapy for chronic hepatitis C. It provides dual-action viral inhibition, high cure rates, and a convenient once-daily regimen, supporting long-term liver health and reducing the risk of cirrhosis and HCV-related complications.